Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Liabilities and Shareholders Equity (2023 - 2025)

Nuvation Bio (NUVB) has disclosed Liabilities and Shareholders Equity for 3 consecutive years, with $594.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 10.02% to $594.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.3 billion, a 0.69% increase, with the full-year FY2025 number at $594.8 million, up 10.02% from a year prior.
  • Liabilities and Shareholders Equity was $594.8 million for Q4 2025 at Nuvation Bio, down from $601.6 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $657.1 million in Q1 2023 to a low of $492.5 million in Q1 2025.
  • A 3-year average of $600.6 million and a median of $607.3 million in 2024 define the central range for Liabilities and Shareholders Equity.
  • Biggest YoY gain for Liabilities and Shareholders Equity was 10.02% in 2025; the steepest drop was 19.68% in 2025.
  • Nuvation Bio's Liabilities and Shareholders Equity stood at $621.5 million in 2023, then fell by 13.01% to $540.6 million in 2024, then grew by 10.02% to $594.8 million in 2025.
  • Per Business Quant, the three most recent readings for NUVB's Liabilities and Shareholders Equity are $594.8 million (Q4 2025), $601.6 million (Q3 2025), and $647.2 million (Q2 2025).